(Z)-2-(3-(4-methylbenzylidene)-6-fluoro-2-methyl-3H-inden-1-yl)acetic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚和异茚
• 英文名称: (Z)-2-(3-(4-methylbenzylidene)-6-fluoro-2-methyl-3H-inden-1-yl)acetic acid
• 英文别名: (Z)-2-(5-fluoro-2-methyl-1-(4-methylbenzylidene)-1H-inden-3-yl)acetic acid；2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylphenyl)methylidene]inden-1-yl]acetic acid
• 化学式: C₂₀H₁₇FO₂
• 分子量: 308.352
• InChiKey: BZRWYHUKBKGVAO-MFOYZWKCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• METHODS AND COMPOSITIONS RELATED TO A RETINOID RECEPTOR-SELECTIVE PATHWAY
  申请人：Zhang Xiao-kun

  公开号：US20150266842A1

  公开（公告）日：2015-09-24

  Provided herein are methods and compositions related to a retinoid receptor-selective pathway. As described herein, this pathway can be targeted to manipulate a tumor microenvironment. For example, the methods and compositions described herein can be used to induce apoptosis in a cancer cell. Further, the compositions described herein, including Sulindac and analogs thereof, can be used to target this pathway for the treatment or prevention of cancer in human patients.

  本文提供了与视黄醛受体选择性通路相关的方法和组合物。如本文所述，该通路可以被定向用于操纵肿瘤微环境。例如，本文描述的方法和组合物可用于诱导癌细胞凋亡。此外，包括舒林达克及其类似物在内的本文描述的组合物可用于针对该通路治疗或预防人类患者的癌症。
• Methods and compositions related to retinoid receptor-selective pathway
  申请人：Sanford Burnham Prebys Medical Discovery Institute

  公开号：US10087156B2

  公开（公告）日：2018-10-02

  Provided herein are methods and compositions related to a retinoid receptor-selective pathway. As described herein, this pathway can be targeted to manipulate a tumor microenviroment. For example, the methods and compositions described herein can be used to induce apoptosis in a cancer cell. Further, the compositions described herein, including Sulindac and analogs thereof, can be used to target this pathway for the treatment or prevention of cancer in human patients.

  本文提供了与视黄醇受体选择性途径有关的方法和组合物。如本文所述，该通路可作为靶向来操纵肿瘤微环境。例如，本文所述的方法和组合物可用来诱导癌细胞凋亡。此外，本文所述的组合物，包括舒林酸及其类似物，可用于靶向这一途径，治疗或预防人类患者的癌症。
• Method of treating or preventing Ras-mediated diseases
  申请人：ADT Pharmaceuticals, LLC

  公开号：US11198679B2

  公开（公告）日：2021-12-14

  Disclosed are compounds, for example, a compound of formula I, wherein R, R0, R1-R8, n, X, Y, Y′, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition for example, cancer, mediated by the ras gene.

  本发明公开了化合物，例如，具有式I的化合物，其中R、R0、R1-R8、n、X、Y、Y’和E如本文所述，含有此类化合物的药物组合物，以及用于治疗或预防由ras基因介导的疾病或病症（例如癌症）的方法。
• Derivatives of sulindac, use thereof and preparation thereof
  申请人：Piazza Gary

  公开号：US20070244122A1

  公开（公告）日：2007-10-18

  Derivatives of sulindac are provided along with pharmaceutical compositions containing them and use for precancerous conditions and treating cancer. Derivatives of sulindac are also suitable for treating chronic inflammatory conditions. A method for preparing the derivatives is also provided.
• CATALYTIC ANTIOXIDANTS AND METHODS OF USE
  申请人：Weissbach Herbert

  公开号：US20090069428A1

  公开（公告）日：2009-03-12

  The invention provides small molecules that act as catalytic antioxidants and methods of use thereof. The compounds can repeatedly bind and destroy reactive oxygen species by serving as substrates for enzymes of the methionine sulfoxide reductase (Msr) class. Some embodiments of the catalytic antioxidant compounds are derived from drugs with anti-inflammatory activity due to inhibition of cyclooxygenase enzymes.